Palisade Bio Q2 2026: Phase 2 UC Trial Enrollment Nears, IND for Crohn's on Track, Cash Runway Intact

What happened

Palisade Bio’s Q2 2026 update confirms that the Phase 2 ASCENTRA-UC trial for PALI-2108 will begin enrolling patients in the second half of 2026, with primary efficacy data expected in late 2027. The company also plans to submit an IND for a Phase 2 Crohn’s disease trial by year‑end, signaling steady pipeline progression. Management reaffirmed that the $138 million raised in 2025 provides sufficient cash to fund operations through these key clinical readouts, alleviating near‑term financing concerns. This execution aligns with the base scenario outlined in our prior analysis, though the stock remains a binary bet on PDE4 inhibition efficacy in IBD. While regulatory clearance appears smooth so far, the absence of any randomized data keeps PALI‑2108’s value speculative and heavily dependent on future trial success.

Implication

Successful enrollment and IND filings confirm Palisade’s operational execution and cash through Phase 2 readouts, modestly bolstering the investment case. However, investors face an 18‑month wait for efficacy results, with no value‑inflecting catalysts before late 2027. The risk‑reward remains roughly balanced; attractive entry persists below $1.30, while any rally toward $3.00 warrants trimming given single‑asset concentration and extended timeline.

Thesis delta

Palisade’s clinical advancement aligns with prior guidance, reducing near‑term regulatory uncertainty and validating the 2025 capital raise. However, the investment case remains contingent on Phase 2 efficacy results in 2H 2027, with no value‑inflecting catalysts in the interim. The thesis tilts cautiously positive but awaits proof‑of‑concept.